Cellectis S.a. Share Price (NASDAQ: CLLS)

$2.91

▲

0.06

(2.11%)

Live

Last updated on August 18, 2025 at 11:43 PM IST

$₹

Check the interactive Cellectis S.a. Stock chart to analyse performance

Cellectis S.a. stock performance

as on August 18, 2025 at 11:43 PM IST

Today's Low:$2.80
Today's High:$2.91
$2.91
3.78%
Downside
Day's Volatility :3.78%
Upside
0.0%
52 Weeks Low:$1.10
52 Weeks High:$3.24
$2.91
62.2%
Downside
52 Weeks Volatility :66.05%
Upside
10.19%

Cellectis S.a. Stock Returns

Period	Cellectis S.a.	Sector (Health Care)	Index (Russel 2000)
3 Months	83.87%	2.3%	0.0%
6 Months	80.95%	-5.8%	0.0%
1 Year	33.8%	-10.9%	0.0%
3 Years	-16.67%	2.8%	-11.6%

Cellectis S.a. Key Stats

Check Cellectis S.a. key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$2.85
Open	$2.92
Today's High	$2.91
Today's Low	$2.8
Market Capitalization	$298.5M
Today's Volume	$102.8K
52 Week High	$3.24
52 Week Low	$1.1
Revenue TTM	$63.4M
EBITDA	$-33.0M
Earnings Per Share (EPS)	$-0.59
Profit Margin	-93.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-48.02%

Stock Returns calculator for Cellectis S.a. Stock including INR - Dollar returns

The Cellectis S.a. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Cellectis S.a. investment value today

Current value as on today

₹1,40,693

Returns

₹40,693

(+40.69%)

Returns from Cellectis S.a. Stock

₹36,620 (+36.62%)

Dollar Returns*

₹4,073 (+4.07%)

Indian investors sentiment towards Cellectis S.a. Stock

133%

Period: Jul 18, 2025 to Aug 17, 2025. Change in 30 Days versus previous period

Search interest for Cellectis S.a. Stock from India on INDmoney has increased by 133% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Cellectis S.a.

Name
Holdings %
Name
Holdings %
Long Focus Capital Management, LLC
4.70%
B Group, Inc
3.25%
UBS Asset Mgmt Americas Inc
3.17%
Macquarie Group Ltd
0.23%
Millennium Management LLC
0.10%
Morgan Stanley - Brokerage Accounts
0.09%

Analyst Recommendation on Cellectis S.a. Stock

Rating

Trend

Buy

85%Buy

14%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Cellectis S.a.(by analysts ranked 0 to 5 stars)

Cellectis S.a. Share Price Target

What analysts predicted

Upside of 92.44%

Target:

$5.60

Current:

$2.91

Cellectis S.a. share price target is $5.60, a slight Upside of 92.44% compared to current price of $2.91 as per analysts' prediction.

Cellectis S.a. Stock Insights

Price Movement
In the last 1 month, CLLS stock has moved up by 56.6%
Increasing Revenue
Revenue is up for the last 2 quarters, 10.65M → 16.93M (in $), with an average increase of 37.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, 5.92M → -24.03M (in $), with an average decrease of 219.4% per quarter
CLLS vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 67.4% return, outperforming this stock by 30.7%
CLLS vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 100.9% return, outperforming this stock by 121.1%
Price to Sales
ForCLLS every $1 of sales, investors are willing to pay $4.5, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.6 for every $1 of sales.

Cellectis S.a. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$15.2M	↑ 19.32%
Net Income	$-90.7M	↑ 15.24%
Net Profit Margin	-597.01%	↑ 21.11%

	FY20	Y/Y Change
Revenue	$73.9M	↑ 386.83%
Net Income	$-72.6M	↓ 19.98%
Net Profit Margin	-98.14%	↑ 498.87%

	FY21	Y/Y Change
Revenue	$73.9M	↑ 0.0%
Net Income	$-86.3M	↑ 18.89%
Net Profit Margin	-116.68%	↓ 18.54%

	FY22	Y/Y Change
Revenue	$19.2M	↓ 74.08%
Net Income	$-98.7M	↑ 14.38%
Net Profit Margin	-514.78%	↓ 398.1%

	FY23	Y/Y Change
Revenue	$755.0K	↓ 96.06%
Net Income	$-101.1M	↑ 2.4%
Net Profit Margin	-13.4K%	↓ 12870.52%

	FY24	Y/Y Change
Revenue	$41.5M	↑ 5397.48%
Net Income	$-36.8M	↓ 63.62%
Net Profit Margin	-88.57%	↑ 13296.73%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$4.5M	↑ 1500.0%
Net Income	$5.6M	↓ 113.17%
Net Profit Margin	124.62%	↑ 15270.2%

	Q2 FY24	Q/Q Change
Revenue	$8.1M	↑ 78.03%
Net Income	$-25.3M	↓ 547.81%
Net Profit Margin	-313.48%	↓ 438.1%

	Q3 FY24	Q/Q Change
Revenue	$16.2M	↑ 100.97%
Net Income	$-23.1M	↓ 8.76%
Net Profit Margin	-142.32%	↑ 171.16%

	Q4 FY24	Q/Q Change
Revenue	$12.7M	↓ 21.5%
Net Income	$5.9M	↓ 125.69%
Net Profit Margin	46.57%	↑ 188.89%

	Q1 FY25	Q/Q Change
Revenue	$10.7M	↓ 16.21%
Net Income	$-18.1M	↓ 406.11%
Net Profit Margin	-170.14%	↓ 216.71%

	Q2 FY25	Q/Q Change
Revenue	$16.9M	↑ 58.95%
Net Income	$-24.0M	↑ 32.58%
Net Profit Margin	-141.92%	↑ 28.22%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$3.8M	↓ 61.99%

	FY20	Y/Y Change
Profit	$37.7M	↑ 891.94%

	FY21	Y/Y Change
Profit	$37.7M	↑ 0.0%

	FY22	Y/Y Change
Profit	$17.4M	↓ 53.82%

	FY23	Y/Y Change
Profit	$18.0K	↓ 99.9%

	FY24	Y/Y Change
Profit	$21.6M	↑ 120072.22%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$-41.0K	↓ 99.19%

	Q2 FY24	Q/Q Change
Profit	$3.3M	↓ 8229.27%

	Q3 FY24	Q/Q Change
Profit	$11.5M	↑ 244.43%

	Q4 FY24	Q/Q Change
Profit	$10.2M	↓ 11.13%

	Q1 FY25	Q/Q Change
Profit	$8.6M	↓ 15.31%

	Q2 FY25	Q/Q Change
Profit	$11.9M	↑ 37.22%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-69.1M	↑ 1.47%
Investing Cash Flow	$-35.9M	↓ 200.7%
Financing Cash Flow	$-3.9M	↓ 101.63%

	FY20	Y/Y Change
Operating Cash Flow	$-80.3M	↑ 16.08%
Investing Cash Flow	$-54.3M	↑ 51.49%
Financing Cash Flow	$27.3M	↓ 807.46%

	FY21	Y/Y Change
Operating Cash Flow	$-104.6M	↑ 30.28%
Investing Cash Flow	$7.3M	↓ 113.39%
Financing Cash Flow	$47.5M	↑ 73.94%

	FY22	Y/Y Change
Operating Cash Flow	$-87.4M	↓ 16.37%
Investing Cash Flow	$-2.8M	↓ 137.93%
Financing Cash Flow	$1.1M	↓ 97.59%

	FY23	Y/Y Change
Operating Cash Flow	$-24.7M	↓ 71.7%
Investing Cash Flow	$-15.5M	↑ 461.75%
Financing Cash Flow	$82.9M	↑ 7137.12%

	FY24	Y/Y Change
Operating Cash Flow	$23.0M	↓ 192.9%
Investing Cash Flow	$-102.8M	↑ 562.85%
Financing Cash Flow	$89.1M	↑ 7.54%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-23.5M	↓ 159.43%
Investing Cash Flow	$-2.1M	↓ 84.98%
Financing Cash Flow	$12.1M	↓ 70.92%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$52.0M	↓ 320.97%
Investing Cash Flow	$-106.4M	↑ 5089.13%
Financing Cash Flow	$78.7M	↑ 549.0%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-5.8M	↓ 111.21%
Investing Cash Flow	$22.3M	↓ 120.98%
Financing Cash Flow	$-4.2M	↓ 105.36%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-47.0K	↓ 99.19%
Investing Cash Flow	$-16.7M	↓ 174.6%
Financing Cash Flow	$2.9M	↓ 169.35%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-17.2M	↑ 36410.64%
Investing Cash Flow	$4.2M	↓ 125.35%
Financing Cash Flow	$-4.1M	↓ 239.83%

Cellectis S.a. Technicals Summary

Sell

Neutral

Buy

Cellectis S.a. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Cellectis S.a. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Cellectis S.a.	55.74%	80.95%	33.8%	-16.67%	-85.08%
Regeneron Pharmaceuticals, Inc.	6.39%	-14.65%	-51.51%	-6.14%	-7.82%
Beone Medicines Ltd	10.08%	34.96%	66.94%	83.8%	36.85%
Vertex Pharmaceuticals Incorporated	-14.33%	-15.0%	-19.52%	31.35%	45.44%
Alnylam Pharmaceuticals, Inc.	40.06%	79.56%	63.55%	107.86%	227.15%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Cellectis S.a.	NA	NA	0.0	-0.61	-0.48	-0.07	NA	1.34
Regeneron Pharmaceuticals, Inc.	14.62	14.62	1.19	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.33	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.94	27.94	0.58	18.04	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Cellectis S.a.	Buy	$298.5M	-85.08%	NA	-93.0%
Regeneron Pharmaceuticals, Inc.	Buy	$61.5B	-7.82%	14.62	31.37%
Beone Medicines Ltd	NA	$38.8B	36.85%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.7B	45.44%	27.94	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$58.0B	227.15%	NA	-12.96%

About Cellectis S.a.

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company was founded in 1999 and is headquartered in Paris, France.

Organization	Cellectis S.a.
Employees	216
CEO	Dr. David J. Sourdive Ph.D.
Industry	Health Technology

Key Management of Cellectis S.a.

Name	Title
Dr. Andre Choulika Ph.D.	Co-Founder, CEO & Director
Dr. David J. Sourdive Ph.D.	Co-Founder, Deputy CEO, Executive VP of CMC & Manufacturing and Director
Mr. Arthur Stril	CFO & Chief Business Officer
Valerie Cros	Principal Financial Officer & Principal Accounting Officer
Mr. Jean Charles Epinat Ph.D.	Chief Technological Officer
Dr. Philippe Duchateau Ph.D.	Chief Scientific Officer
Ms. Marie-Bleuenn Terrier	General Counsel & Secretary of the Board of Directors
Pascalyne Wilson	Director of Communications
Ms. Kyung Nam-Wortman	Executive VP & Chief Human Resources Officer
Mr. Stephan Reynier M.Sc.	Chief Regulatory & Pharmaceutical Compliance Officer

Important FAQs about investing in CLLS Stock from India :

What is Cellectis S.a. share price today?

Cellectis S.a. share price today is $2.91 as on August 18, 2025 at 11:43 PM IST. Cellectis S.a. share today touched a day high of $2.91 and a low of $2.80.

What is the 52 week high and 52 week low for Cellectis S.a. share?

Cellectis S.a. share touched a 52 week high of $3.24 and a 52 week low of $1.10. Cellectis S.a. stock price today, August 18, 2025 at 11:43 PM IST is trending at $2.91, lower by 10.19% versus the 52 week high.

How to invest in Cellectis S.a. Stock (CLLS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Cellectis S.a. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Cellectis S.a. Shares that will get you 0.5155 shares as per Cellectis S.a. share price of $2.91 per share as on August 18, 2025 at 11:43 PM IST.

What is the minimum amount required to buy Cellectis S.a. Stock (CLLS) from India?

Indian investors can start investing in Cellectis S.a. (CLLS) shares with as little as ₹87.3775 or $1 (as of August 18, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹873.77 in Cellectis S.a. stock (as per the Rupee-Dollar exchange rate as on August 18, 2025). Based on Cellectis S.a. share’s latest price of $2.91 as on August 18, 2025 at 11:43 PM IST, you will get 3.4364 shares of Cellectis S.a.. Learn more about fractional shares .

What are the returns that Cellectis S.a. has given to Indian investors in the last 5 years?

Cellectis S.a. stock has given -85.08% share price returns and 16.91% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?